|
|
|
| home > white papers > Overcoming research challenges with Adaptive Trials - PCI Pharma Services |
|
|
 WHITE PAPERS |
|
PCI Pharma Services
|
|
Overcoming research challenges with Adaptive Trials
|
|
There has been cause for concern within the pharmaceutical industry over
the last five years, regarding increasing research and development
costs, combined with a fall in the number of new drugs brought to
market. In an attempt to overcome this issue there has been a
significant rise in the use of adaptive clinical trial designs, whilst
saving time and money as well as facilitating more effective decision
making. One of the biggest challenges that pharmaceutical companies have
experienced has been delivering compliant clinical trials supplies
across diverse patient populations in the relatively short timeframes
that adaptive trial designs require, remaining focused on ensuring that
patient compliance and product quality is in no way compromised. This
demand has led to the launch of fast response services that support
Research and Development in responding to changing dosing regimens
mid-trial.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
PCI Clinical Services Announces New Facility Dedicated to Clinical Trial Returns
Philadelphia, USA – October 15, 2018. Leading international pharmaceutical outsourcing services provider PCI Clinical Services (PCI) has announced the completion of a dedicated Returns Management facility at its Clinical Services Center of Excellence at Bridgend, UK. PCI provides a full service Returns Management service for clients, providing visibility and accountability in returning investigational drug product from investigational sites at the conclusion of a clinical study. Returning and reconciling Investigational Medicinal Product (IMP) on completion of a study is a critical part of a Clinical trial and can require complex reverse logistics. Trial outcomes can be impacted if Returns are not processed efficiently and precisely.
More info >> |
|
 |
White Papers |
 |
|
High Potency Drugs – from Molecule to Market
PCI Pharma Services
PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >> |
|
 |
Industry Events |
 |
Pre-Filled Syringes & Injectable Drug Devices Europe
16-17 January 2019, Copthorne Tara Hotel, London
SMi is proud to present their 11th annual European conference and
exhibition, within the Pre-Filled Syringes series: Pre-Filled Syringes &
Injectable Drug Devices Europe. The event will take place on the 16th-17th of
January 2019, in London.
More info >> |
|
|
|
